Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience
Endocrine · 2024
DOI: 10.1007/s12020-024-04029-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine, 2024. Verfasst von David Tak Wai Lui und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong. Hauptthemen laut MEDLINE: Naltrexone, Obesity, Bupropion, Anti-Obesity Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: iNova Pharmaceuticals.
Abstract (Originalsprache)
Purpose
Naltrexone-bupropion (Contrave®) has shown efficacy and safety in large randomised controlled trials, predominantly comprising Caucasians. Data are limited in Asian populations. We carried out a retrospective matched cohort study of Chinese patients with obesity to evaluate the efficacy and safety of naltrexone-bupropion in real-world clinical practice.
Methods
We performed a retrospective matched cohort study of Chinese patients with obesity managed in the Obesity Clinic of Queen Mary Hospital in Hong Kong between 1 January 2016 and 31 December 2020. Electronic health records of patients treated with naltrexone-bupropion were retrieved for body weight and height, obesity-related metabolic parameters, and adverse events over a 12-month period. Age- and sex-matched controls from the Obesity Clinic who were only on self-directed lifestyle management were identified for comparison of weight changes. General linear models were used to analyse the change in body weight over 12 months.
Results
Thirty-seven patients treated with naltrexone-bupropion were included (mean age 42.2 ± 8.4 years, 54.1% men, baseline body mass index 37.3 ± 4.6 kg/m 2 ), and 37 age- and sex-matched controls were included. Among the 37 naltrexone-bupropion-treated patients, the mean weight loss was 9.2 ± 5.2% at 6 months and 9.7 ± 8.1% at 12 months, which were significantly more than in controls (p < 0.001). Improvements in the obesity-related parameters were observed in association with weight loss over 12 months. Ten patients (27.0%) discontinued naltrexone-bupropion due to side effects, mainly neurological and gastrointestinal manifestations, within the first 12 months.
Conclusion
We demonstrated real-world efficacy and safety of naltrexone-bupropion among Chinese patients with obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
- Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong. micheleyuen@hotmail.com.
Förderung
- iNova Pharmaceuticals
Zitieren
APA
Lui, D. T. W., Tsoi, K. H., Fong, C. H. Y., Jiang, N. S., Chow, W. S., & Yuen, M. M. A. (2024). Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience. Endocrine. https://doi.org/10.1007/s12020-024-04029-2
Vancouver
Lui DTW, Tsoi KH, Fong CHY, Jiang NS, Chow WS, Yuen MMA. Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience. Endocrine. 2024. doi:10.1007/s12020-024-04029-2
BibTeX
@article{Lui2024,
author = {Lui, David Tak Wai and Tsoi, Kimberly Hang and Fong, Carol Ho Yi and Jiang, Nancy Su and Chow, Wing Sun and Yuen, Michele Mae Ann},
title = {Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: A single-centre experience},
journal = {Endocrine},
year = {2024},
doi = {10.1007/s12020-024-04029-2}
}
EUVIMED